Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and ...

Dupixent (dupilumab) is tipped to be the market ... Sanofi says there has been more than 200 applications to receive the drug under the system, which ceases once a drug gains marketing approval.

Monday closed down -2.70%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -2.08%, and the Nasdaq 100 Index ($IUXX) ...

The stock has a fifty day moving average price of $52.65 and a 200 day moving average price ... The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases ...

The charges stem from an incident that occurred on April 22, 2024, when Thomas was stopped by a Riviera Beach police officer ...

“In our practice here, we now have about 200 patients receiving regular injections ... improve for other drugs such as dupilumab (Dupixent; Regeneron, Sanofi) as practices have learned ...